![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
19th edition of the Asia’s largest life-sciences and Health Tech forum BioAsia, the annual flagship event of Government of Telangana will be held during February 24th and 25th, 2022 in a virtual format. The theme of this year’s edition is ‘Future Ready’ and would focus on exploring industry’s current position and future potential, new approaches and capabilities required to be ready as the life sciences industry develops its future growth strategy. The future growth will be driven by shift from “volume focus” to “volume + value focus”. The industry needs to continue building on its strength and at the same time make a giant leap towards innovation. New capabilities need to be introduced across the business functions to bring efficiencies and to help industry move up the value chain.
The event will bring together leaders from the industry, research, innovation and governments from more than 70 countries to address the wide-ranging needs of the healthcare system. The conference will provide a unique opportunity to Pharma and Biotech companies, CROs, CMOs, CDMOs, Biotech start-ups, Academic Institutions, Scientists and Researchers, Policy Makers, and Regulatory Experts across the globe to assess industry’s current position and deliberate on the imperatives for future growth and other insightful topics related to the life sciences industry.
A picture containing text Description automatically generatedThe two-day event will witness a wide array of panels focussing on the Future of the Life-Sciences amid the ongoing pandemic and the ways the industry must be focussing on to combat any future pandemics. Over the years, the event has immensely benefitted from its participant history including the likes of several Nobel Prize winners like Dr. Kurt Wuthrich, Ada Yonath, Harald Zur Hausen, Barry Marshall, Martin J Evans, Lasker Awardees and eminent industry leaders like Dr. Vas Narasimhan (CEO, Novartis), Dr. Paul Stoffeis (VC and CSO, Johnson & Johnson), Dr. Seth Berkely (CEO, GAVI), Mr. Satya Nadella (CEO, Microsoft), among others, in addition to the Asian, American, African and European country ministers and delegations. This year also the event will have a stellar lineup of speakers during the 2-day event.
Unveiling the dates and theme of the event, Mr. KT Rama Rao, Minister for Industries & Commerce (I&C) and Information Technology (IT), Government of Telangana, said “Hyderabad has cemented its position as the life sciences hub of the Country and the vaccine capital of the world. BioAsia has been an integral part of this extraordinary growth story and the event continues to help us in showcasing the prowess of Hyderabad in particular and India in general to the world. I invite stakeholders from around the world to take active part in the deliberations”
Explaining the significance of the global conclave, Mr. Jayesh Ranjan, IAS, Principal Secretary, the Industries & Commerce (I&C) and Information Technology (IT), Government of Telangana said, “BioAsia is an excellent global forum for biotechnology, pharma and healthcare industries, academia and start-ups to showcase their innovations and network for better connections. Over the years, it has been instrumental in promoting India and Telangana as key enablers in the global life sciences and allied sectors. Over the last 18 years, BioAsia convention has seen over 270 Lols, Bilateral co-operation agreements & MoUs getting signed along with trade & investment to an extent of USD 2.6 billion so far.”
“The first virtual edition held last year was extremely successful and impactful in continuing the dialogue in these unprecedented times. The 2021 event witnessed around 31,450 participants representing 72 countries with 60 high-profile speakers. We are confident that the 19th edition will bring together some of the most influential leaders to discuss about a wide range of topics concerning the opportunities and challenges in the healthcare sector” added Mr. Shakthi Nagappan, CEO of BioAsia and Director of Life Sciences, GoTS while commenting on BioAsia 2022.
Over the course of 18 years, the event has witnessed participation from more than 20,000 leaders representing over 100 Countries and has conducted more than 20,000 partnering meetings. Keeping in line with the COVID-19 safety restrictions, the event will continue to be in a virtual format like the last edition.
About BioAsia: BioAsia is born with a vision to enhance, enrich and encourage newer innovations, path-breaking discoveries and effective solutions in the biotechnology industry by offering a vibrant global platform for convergence of the key stakeholders – Biotech & Biopharma Companies, research institutions, academia, investors, service providers, policymakers, regulators, and analysts. BioAsia is focused in its efforts – to drive the growth of the industry by enabling an effective environment for fostering collaborations, JV’s M&A’s; ensure knowledge and experience sharing by global industry players to benefit all stakeholders; promote innovations and initiatives through appropriate awards and recognitions; play a pivotal role in advocating issues to the policymakers and chartering the road-map of biotechnology. BioAsia is a dynamic platform for companies -to exhibit, launch and showcase their unique strengths, products, and services. BioAsia is playing the role of a key catalyst in mobilizing all elements that are required to drive the growth of the emerging industry of Biotechnology as well as optimize the immense business potential of biotech. On a larger level, BioAsia is working to drive a global transformation from the treatment of illness to wellness.
About FABA (Federation of Asian Biotech Associations): The Federation of Asian Biotech Associations [FABA], is a non-profit registered society engaged in various activities related to promoting Biotechnology in Asian countries. FABA, headquartered at Hyderabad made its humble beginning in 2004 and has achieved a significant landmark in creating a common platform for interaction among member countries and discuss the issues of common interest for improving the biotech space including Technology Transfer, resource sharing, business collaborations, Industry-Academia linkage, cross border trade, and investments, etc. among its member countries., FABA has a strong network base in 20 Asian countries including China, India, Bangladesh, Malaysia, Philippines, Russia, Kazakhstan, Pakistan, Israel, Iran, Indonesia, Nepal, Japan, South Korea, Singapore, Thailand, Sri Lanka and, UAE. Besides, FABA has entered into working understandings with Non-Asian organizations like the European Federation of Biotechnology, Biocat (Spain), Maryland India Business Round Table (USA), Bio Industry Park (Italy) and Association of German Biotech companies (Germany), etc.
